Search

Your search keyword '"Neukam K"' showing total 238 results
Start Over Author "Neukam K"
238 results on '"Neukam K"'

2. Liver stiffness predicts the response to direct-acting antiviral-based therapy against chronic hepatitis C in cirrhotic patients

Author

Neukam, K., Morano-Amado, L. E., Rivero-Juárez, A., Macías, J., Granados, R., Romero-Palacios, A., Márquez, M., Merino, D., Ortega, E., Alados-Arboledas, J. C., Cucurull, J., Omar, M., Ryan-Murua, P., Pineda, J. A., and On behalf of the Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC and Grupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR/Red de Investigación en SIDA (RIS-HEP07)

Published
2017
Full Text
View/download PDF

4. Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain

Author

Rivero-Juarez, A., Gutierrez-Valencia, A., Castaño, M., Merino, D., Neukam, K., Ríos-Villegas, M. J., Lopez-Ruz, M. A., Jiménez-Aguilar, P., Marquez, M., Collado, A., Gomez-Vidal, A., Hernandez-Quero, J., Tellez, F., Fernandez-Fuertes, E., Rivero, A., López-Cortés, L. F., and on behalf of Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)

Published
2015
Full Text
View/download PDF

5. Impact of HIV infection on sustained virological response to treatment against hepatitis C virus with pegylated interferon plus ribavirin

Author

Monje-Agudo, P., Castro-Iglesias, A., Rivero-Juárez, A., Martínez-Marcos, F., Ortega-González, E., Real, L. M., Pernas, B., Merchante, N., Cid, P., Macías, J., Merino, M. D., Rivero, A., Mena, A., Neukam, K., Pineda, J. A., and from the Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC

Published
2015
Full Text
View/download PDF

6. Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia

Author

Mira, J. A., Neukam, K., López-Cortés, L. F., Rivero-Juárez, A., Téllez, F., Girón-González, J. A., de los Santos-Gil, I., Ojeda-Burgos, G., Merino, D., Ríos-Villegas, M. J., Collado, A., Torres-Cornejo, A., Macías, J., Rivero, A., Pérez-Pérez, M., Pineda, J. A., On behalf of the Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI), and Red de Investigación en SIDA (RIS-HEP07)

Published
2015
Full Text
View/download PDF

11. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies

Author

Wei, F, Gaisa, MM, D'Souza, G, Xia, N, Giuliano, AR, Hawes, SE, Gao, L, Cheng, S-H, Dona, MG, Goldstone, SE, van der Loeff, MFS, Neukam, K, Meites, E, Poynten, IM, Dai, J, Combes, J-D, Wieland, U, Burgos, J, Wilkin, TJ, Hernandez, AL, Diaz, MI, Hidalgo-Tenorio, C, Arredondo, MV, Nyitray, AG, Wentzensen, N, Chow, EP, Smelov, V, Nowak, RG, Phanuphak, N, Woo, YL, Choi, Y, Hu, Y, Schofield, AM, Woestenberg, PJ, Chikandiwa, AT, Hickey, AC, de Pokomandy, A, Murenzi, G, Pere, H, del Pino, M, Ortiz, AP, Charnot-Katsikas, A, Liu, X, Chariyalertsak, S, Strong, C, Ong, JJ, Yunihastuti, E, Etienney, I, Ferre, VM, Zou, H, Segondy, M, Chinyowa, S, Alberts, CJ, Clifford, GM, Wei, F, Gaisa, MM, D'Souza, G, Xia, N, Giuliano, AR, Hawes, SE, Gao, L, Cheng, S-H, Dona, MG, Goldstone, SE, van der Loeff, MFS, Neukam, K, Meites, E, Poynten, IM, Dai, J, Combes, J-D, Wieland, U, Burgos, J, Wilkin, TJ, Hernandez, AL, Diaz, MI, Hidalgo-Tenorio, C, Arredondo, MV, Nyitray, AG, Wentzensen, N, Chow, EP, Smelov, V, Nowak, RG, Phanuphak, N, Woo, YL, Choi, Y, Hu, Y, Schofield, AM, Woestenberg, PJ, Chikandiwa, AT, Hickey, AC, de Pokomandy, A, Murenzi, G, Pere, H, del Pino, M, Ortiz, AP, Charnot-Katsikas, A, Liu, X, Chariyalertsak, S, Strong, C, Ong, JJ, Yunihastuti, E, Etienney, I, Ferre, VM, Zou, H, Segondy, M, Chinyowa, S, Alberts, CJ, and Clifford, GM

Abstract

BACKGROUND: Robust age-specific estimates of anal human papillomavirus (HPV) and high-grade squamous intraepithelial lesions (HSIL) in men can inform anal cancer prevention efforts. We aimed to evaluate the age-specific prevalence of anal HPV, HSIL, and their combination, in men, stratified by HIV status and sexuality. METHODS: We did a systematic review for studies on anal HPV infection in men and a pooled analysis of individual-level data from eligible studies across four groups: HIV-positive men who have sex with men (MSM), HIV-negative MSM, HIV-positive men who have sex with women (MSW), and HIV-negative MSW. Studies were required to inform on type-specific HPV infection (at least HPV16), detected by use of a PCR-based test from anal swabs, HIV status, sexuality (MSM, including those who have sex with men only or also with women, or MSW), and age. Authors of eligible studies with a sample size of 200 participants or more were invited to share deidentified individual-level data on the above four variables. Authors of studies including 40 or more HIV-positive MSW or 40 or more men from Africa (irrespective of HIV status and sexuality) were also invited to share these data. Pooled estimates of anal high-risk HPV (HR-HPV, including HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and HSIL or worse (HSIL+), were compared by use of adjusted prevalence ratios (aPRs) from generalised linear models. FINDINGS: The systematic review identified 93 eligible studies, of which 64 contributed data on 29 900 men to the pooled analysis. Among HIV-negative MSW anal HPV16 prevalence was 1·8% (91 of 5190) and HR-HPV prevalence was 6·9% (345 of 5003); among HIV-positive MSW the prevalences were 8·7% (59 of 682) and 26·9% (179 of 666); among HIV-negative MSM they were 13·7% (1455 of 10 617) and 41·2% (3798 of 9215), and among HIV-positive MSM 28·5% (3819 of 13 411) and 74·3% (8765 of 11 803). In HIV-positive MSM, HPV16 prevalence was 5·6% (two of 36) among those age 15-18 y

Published
2021

21. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

Author

Pineda, J.A., primary, Morano-Amado, L.E., additional, Granados, R., additional, Macías, J., additional, Téllez, F., additional, García-Deltoro, M., additional, Ríos, M.J., additional, Collado, A., additional, Delgado-Fernández, M., additional, Suárez-Santamaría, M., additional, Serrano, M., additional, Miralles-Álvarez, C., additional, Neukam, K., additional, Alados-Arboledas, J.C., additional, Albendín, H., additional, Alemán, M.R., additional, del Mar Alonso, M., additional, Asensi, V., additional, Blanco, M.J., additional, Borrallo, J., additional, Cabo, R., additional, Camacho, Á., additional, Casas, M.F., additional, Castro, Á., additional, Cucurull, J., additional, Cuéllar, S., additional, Cuenca, F., additional, de los Santos-Gil, I., additional, Dueñas, C., additional, Fernández, E., additional, Galera, C., additional, Gálvez, M.C., additional, García, D., additional, Geijo-Martínez, P., additional, Gómez, A., additional, Gómez, J.L., additional, Gutiérrez, F., additional, Hernández, J., additional, Llenas-García, J., additional, Mancebo, M., additional, Márquez, M., additional, Martín, J.M., additional, Martínez, L., additional, Martínez-Álvarez, R., additional, Martínez Madrid, O., additional, del Mar Masiá, M., additional, Merchante, N., additional, Merino, D., additional, Monje, P., additional, Nuñez, R., additional, Omar, M., additional, Ortega, E., additional, Padilla, S., additional, Robledano, C., additional, Pelazas, R., additional, Pérez, E., additional, Pérez-Camacho, I., additional, Pérez-Pérez, M., additional, Pernas, B., additional, Portu, J.J., additional, Raffo, M., additional, Real, L.M., additional, Reina, G., additional, Rivero, A., additional, Rivero-Juárez, A., additional, Romero-Palacios, A., additional, Portilla, J., additional, Rubio, P., additional, Ryan-Murua, P., additional, de la Hoya, P.S., additional, Santos, J., additional, Toyas, C., additional, Vera-Méndez, F., additional, Vergara, A., additional, Hernández, M.V., additional, and García, D.V., additional

Published
2017
Full Text
View/download PDF

23. Efficacy of therapy against chronic hepatitis C virus genotype 1 infection in HIV-coinfected patients with several interferon-free DAA combinations: real life data from the HEPAVIR-DAA Cohort

Author

Neukam, K., primary, Téllez, F., additional, Morano-Amado, L.E., additional, Rivero-Juárez, A., additional, Nuño-Álvarez, E., additional, Ríos, M.J., additional, Macías, J., additional, Merino, D., additional, Pérez-Pérez, M., additional, and Pineda, J.A., additional

Published
2017
Full Text
View/download PDF

26. HIV Coinfection Impairs Response to DAA-Based HCV Therapy

Author

Neukam, K., primary, Suárez-Santamaría, M., additional, Rivero-Juárez, A., additional, Romero-Palacios, A., additional, Ortega, E., additional, de los Santos-Gil, I., additional, Cucurull, J., additional, Vera-Méndez, F., additional, and Pineda, J.A., additional

Published
2016
Full Text
View/download PDF

27. Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.

Author

Álvarez‐Ossorio, M. J., Sarmento e Castro, R., Granados, R., Macías, J., Morano‐Amado, L. E., Ríos, M. J., Merino, D., Álvarez, E. N., Collado, A., Pérez‐Pérez, M., Téllez, F., Martín, J. M., Méndez, J., Pineda, J. A., Neukam, K., Alados‐Arboledas, Juan Carlos, Albendín, Helena, Alemán, María Remedios, Alonso, María del Mar, and Asensi, Victor

Subjects
THERAPEUTIC use of interferons, GLOMERULAR filtration rate, HEPATITIS C treatment, HEPATITIS C virus, NEPHROTOXICOLOGY
Abstract

Little data are available on renal toxicity exerted by direct-acting antivirals (DAAs) in real life. The aim of this study was to assess the impact of direct-acting antivirals against hepatitis C virus infection currently used in Spain and Portugal on the estimated glomerular filtration rate (eGFR) in clinical practise. From an international, prospective multicohort study, patients treated with DAAs for at least 12 weeks and with eGFR ≥30 mL/min per 1.73 m2 at baseline were selected. eGFR was determined using the CKD-EPI formula. A total of 1131 patients were included; 658 (58%) were HIV/HCV-coinfected patients. Among the 901 patients treated for 12 weeks, median (interquartile range) eGFR was 100 (87-107) at baseline vs 97 (85-105) mL/min per 1.73 m2 at week 12 of follow-up (FU12) post-treatment (P < .001). For HIV-coinfected subjects who received tenofovir plus a ritonavir-boosted HIV protease inhibitor (PI/r), baseline vs FU12 eGFR were 104 (86-109) vs 104 (91-110) mL/min per 1.73 m2 (P = .913). Among subjects receiving ombitasvir/paritaprevir with or without dasabuvir, eGFR did not show any significant change. Of 1100 subjects with eGFR >60 mL/min per 1.73 m2 at baseline, 22 (2%) had eGFR <60 mL/min per 1.73 m2 at FU12, but none presented with eGFR <30 mL/min per 1.73 m2. In conclusion, eGFR slightly declines during therapy with all-oral DAAs and this effect persists up to 12 weeks after stopping treatment in subjects with normal to moderately impaired renal function, regardless of HIV status. Concomitant use of tenofovir plus PI/r does not seem to have an impact on eGFR. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

28. Prevalence of hepatitis C virus infection according to the year of birth: identification of risk groups.

Author

Neukam, K., Ridruejo, E., Pérez, P., Campos, R. H., Martínez, A. P., and Di Lello, F. A.

Subjects
*HEPATITIS C virus, *HEPATITIS C diagnosis, *DISEASE prevalence, *VIREMIA, *ALANINE aminotransferase
Abstract

Hepatitis C virus (HCV) screening according to the year of birth is recommended is some countries based on epidemiological data. The aim of this study was to analyze anti-HCV prevalence among people born between 1905 and 2015 in Argentina. Patients attending a tertiary care hospital in Buenos Aires, Argentina, from 2001 to 2015, who had a determination of anti-HCV, were included. Of 22,079 patients analyzed, 1,152 (5.2%; 95% confidence interval [CI]: 4.9%-5.5%) patients showed positive anti-HCV and 729 (3.3%; 95% CI: 3.1%-3.5%) patients showed detectable viremia. Three risk groups were identified (HCV prevalence): low-risk group-outpatient clinics/emergencies (2.8%); intermediate-risk group-in-patients (8%); and high-risk group-dialysis/transplants (27.2%). In the low-risk group, being born in 1973 or before was identified as a cut-off value for the risk of anti-HCV acquisition (area under the receiver-operator characteristic curve: 75.1 [95% asymptotic CI: 0.732-0.770; p < 0.001]). Ninety-one patients born after 1973 (0.8%) showed positive anti-HCV versus 457 individuals born in 1973 or before (5.8%), p < 0.001. In this group, positive anti-HCV was observed in 252 females (2.1%) and 296 males (4.1%), p < 0.001. In a multivariate analysis adjusted for gender, alanine-aminotransferase levels and HIV coinfection, being born in 1973 or before was independently identified as a risk for positive anti-HCV (adjusted odds ratio: 14.234 [95% CI: 9.993-20.277]; p < 0.001). People born in 1973 or before without other risk factors should be included in screening programs to link the highest possible number of HCV-infected patients to appropriate care and treatment. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

29. Sustained virological response in HIV/HCV co‐infected patients without rapid virological response (RVR) on peginterferon‐ribavirin therapy

Author

Labarga, P, Vispo, Me, Guardiola, Jm, Miralles, C, Martín?Carbonero, L, Portu, J, Barreiro, P, Miralles, P, Morello, J, Tellez, Mj, Bancalero, P, Asensi, V, Rallón, Ni, Santos, I, Morano, L, Aguirrebengoa, K, Rios, Mj, Rubio, R, Neukam, K, González?Lahoz, J, and Soriano, V

Subjects
Ribavirin -- Dosage and administration -- Patient outcomes, Erythropoietin -- Dosage and administration -- Patient outcomes, Comorbidity -- Drug therapy -- Patient outcomes, Hepatitis C -- Drug therapy -- Patient outcomes, Peginterferon alfa-2a -- Dosage and administration -- Patient outcomes, HIV infection -- Patient outcomes, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Background Undetectable HCV‐RNA at week 4 of therapy (RVR) is one of the best predictors of SVR in patients with chronic hepatitis C. However, there is scarce information about the [...]

Published
2010
Full Text
View/download PDF

30. Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naive patients

Author

Macías, J., Mallolas, J., López?Cortés, L.F., Cartón, J.A., Domingo, P., Moreno, S., Iribarren, J.A., Neukam, K., Rodrigo, A., Jiménez?Expósito, M.J., and Pineda, J.A.

Subjects
Comorbidity -- Management, Efavirenz -- Dosage and administration, Hepatitis C -- Drug therapy, Nevirapine -- Dosage and administration, HIV infection -- Drug therapy, Company business management, Health
Abstract

7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK, Purpose of the study A wide range of hepatotoxicity rates associated with antiretroviral drugs (ARV) has been reported in different studies. Reasons for this include diverse populations, with different prevalence [...]

Published
2010
Full Text
View/download PDF

31. Wertigkeit der 18-FDG-PET Diagnostik und der Mediastinoskopie zum mediastinalen Lymphknotenstaging des NSCLC

Author

Schimmer, C, Bohrer, T, Neukam, K, and Leyh, R

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Zielsetzung: Bei Patienten mit NSCLC ist das exakte präoperative Lymphknotenstaging von entscheidender Bedeutung, um sowohl die beste therapeutische Option, als auch eine Vergleichbarkeit im Rahmen von klinischen Studie gewährleisten zu können. Methodik: Wir berichten über eine[for full text, please go to the a.m. URL], 16. Jahrestagung der Deutschen Gesellschaft für Thoraxchirurgie

Published
2010
Full Text
View/download PDF

32. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection

Author

Alados-Arboledas, J.C., Albendín, H., Alemán, M.R., del Mar Alonso, M., Asensi, V., Blanco, M.J., Borrallo, J., Cabo, R., Camacho, Á., Casas, M.F., Castro, Á., Cucurull, J., Cuéllar, S., Cuenca, F., de los Santos-Gil, I., Dueñas, C., Fernández, E., Galera, C., Gálvez, M.C., García, D., Geijo-Martínez, P., Gómez, A., Gómez, J.L., Gutiérrez, F., Hernández, J., Llenas-García, J., Mancebo, M., Márquez, M., Martín, J.M., Martínez, L., Martínez-Álvarez, R., Martínez Madrid, O., del Mar Masiá, M., Merchante, N., Merino, D., Monje, P., Nuñez, R., Omar, M., Ortega, E., Padilla, S., Robledano, C., Pelazas, R., Pérez, E., Pérez-Camacho, I., Pérez-Pérez, M., Pernas, B., Portu, J.J., Raffo, M., Real, L.M., Reina, G., Rivero, A., Rivero-Juárez, A., Romero-Palacios, A., Portilla, J., Rubio, P., Ryan-Murua, P., de la Hoya, P.S., Santos, J., Serrano, M., Toyas, C., Vera-Méndez, F., Vergara, A., Hernández, M.V., García, D.V., Pineda, J.A., Morano-Amado, L.E., Granados, R., Macías, J., Téllez, F., García-Deltoro, M., Ríos, M.J., Collado, A., Delgado-Fernández, M., Suárez-Santamaría, M., Miralles-Álvarez, C., and Neukam, K.

Published
2017
Full Text
View/download PDF

33. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.

Author

Macías, J, Monge, P, Mancebo, M, Merchante, N, Neukam, K, Real, LM, and Pineda, JA

Subjects
ANTIVIRAL agents, DRUG interactions, HEPATITIS C, HIV infections, HIV-positive persons, ANTIRETROVIRAL agents, DATA analysis software, DESCRIPTIVE statistics, GENOTYPES, MIXED infections
Abstract

Objectives The aim of the study was to analyse the frequency and degree of potential drug−drug interactions ( DDIs) between direct-acting antivirals ( DAAs) and concomitant medication used by HIV/hepatitis C virus ( HCV)-coinfected patients, including antiretroviral therapy ( ART) and other drugs. Methods All patients with HIV infection and viraemic HCV genotype 1, 3 or 4 coinfection attending a tertiary care centre in Spain (November 2014 to November 2015) were included in the study. DDIs were classified as major, i.e. drugs should not be co-administered, or minor, i.e. close monitoring, dosage alteration or change in timing may be required if drugs are co-administered, following the database recommendations. Results A total of 244 patients were included in the study, of whom 224 (92%) were previous injecting drug users. Major DDIs were found for: paritaprevir-r/ombitasvir plus dasabuvir (3D), in 60 (44%) of 138 individuals with genotype 1; paritaprevir-r/ombitasvir (2D), in 22 (37%) of 60 individuals with genotype 4; sofosbuvir/ledipasvir ( SOF/ LDV), in four (2%) of 198 patients with genotype 1 or 4; simeprevir ( SMV) plus SOF, in 160 (81%) of 198 patients with genotype 1 or 4; daclatasvir ( DCV) plus SOF, in seven (3%) of 244 patients with genotype 1, 3 or 4 ( P < 0.001). Minor DDIs were found for: 3D, in 123 (89%) individuals with genotype 1; 2D, in 52 (87%) individuals with genotype 4; SOF/ LDV, in 154 (78%) patients with genotype 1 or 4; SMV plus SOF, in 129 (65%) patients with genotype 1 or 4; DCV plus SOF, in 149 (61%) patients with genotype 1, 3 or 4 ( P < 0.001). Conclusions Drug−drug interactions between DAAs and ART or other commonly prescribed medications are frequently found among HIV/ HCV-coinfected patients. Potential major and minor DDIs are more frequent with 3D, 2D and SMV plus SOF regimens. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

37. 883 PREDICTION OF RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN BY INTERLEUKIN 28B GENOTYPE IS MODIFIED BY SNPS AT MULTIPLE GENES IN HIV/HEPATITIS C VIRUS GENOTYPE 1/4-COINFECTED PATIENTS

Author

Neukam, K., primary, Caruz, A., additional, Barreiro, P., additional, Rivero-Juárez, A., additional, Merino, D., additional, Márquez, M., additional, P'erez-Navarro, E., additional, Soriano, V., additional, Rivero, A., additional, and Pineda, J.A., additional

Published
2013
Full Text
View/download PDF

38. 882 GENETIC VARIATIONS IN proprotein convertase subtilisin/kexin type 9 (PCSK9) GENE ARE ASSOCIATED WITH RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN IN HEPATITIS C VIRUS GENOTYPE 3-INFECTED PATIENTS

Author

Neukam, K., primary, Caruz, A., additional, Rivero-Juárez, A., additional, Labarga, P., additional, Márquez, M., additional, Real, L.M., additional, Herrero, R., additional, Rivero, A., additional, Soriano, V., additional, and Pineda, J.A., additional

Published
2013
Full Text
View/download PDF

39. 862 THE IMPACT OF IL28B rs12979860 SNP ON THE ASSOCIATION BETWEEN TREATMENT DURATION AND SUSTAINED VIROLOGIC RESPONSE IN HIV/HCV COINFECTED PATIENTS

Author

Mandorfer, M., primary, Reiberger, T., additional, Payer, B.A., additional, Neukam, K., additional, Rivero, A., additional, Puoti, M., additional, Ernst, D., additional, Boesecke, C., additional, Baumgarten, A., additional, Jaroszewicz, J., additional, Grzeszczuk, A., additional, Zangerle, R., additional, Meyer-Olson, D., additional, Rockstroh, J.K., additional, Ferenci, P., additional, Rieger, A., additional, Pineda, J.A., additional, and Peck-Radosavljevic, M., additional

Published
2013
Full Text
View/download PDF

42. 861 THE IMPACT OF IL28B rs12979860 SNP AND ADVANCED LIVER FIBROSIS ON RESPONSE-GUIDED THERAPY IN HIV/HCV COINFECTED PATIENTS OF PARTICULAR CLINICAL INTEREST

Author

Mandorfer, M., primary, Neukam, K., additional, Reiberger, T., additional, Payer, B.A., additional, Rivero, A., additional, Puoti, M., additional, Ernst, D., additional, Boesecke, C., additional, Baumgarten, A., additional, Jaroszewicz, J., additional, Zangerle, R., additional, Meyer-Olson, D., additional, Rockstroh, J.K., additional, Ferenci, P., additional, Rieger, A., additional, Pineda, J.A., additional, and Peck-Radosavljevic, M., additional

Published
2013
Full Text
View/download PDF

43. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

Author

Neukam, K., primary, Almeida, C., additional, Caruz, A., additional, Rivero-Juarez, A., additional, Rallon, N. I., additional, Di Lello, F. A., additional, Herrero, R., additional, Camacho, A., additional, Benito, J. M., additional, Macias, J., additional, Rivero, A., additional, Soriano, V., additional, and Pineda, J. A., additional

Published
2012
Full Text
View/download PDF

45. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

Author

Rivero-Juarez, A., primary, Camacho Espejo, A., additional, Perez-Camacho, I., additional, Neukam, K., additional, Caruz, A., additional, Mira, J. A., additional, Mesa, P., additional, Garcia-Lazaro, M., additional, Torre-Cisneros, J., additional, Pineda, J. A., additional, and Rivero, A., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results